These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18193497)

  • 21. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
    Blanco JL; Montaner JS; Marconi VC; Santoro MM; Campos-Loza AE; Shafer RW; Miller MD; Paredes R; Harrigan R; Nguyen ML; Perno CF; Gonzalez-Hernandez LA; Gatell JM
    AIDS; 2014 Nov; 28(17):2531-9. PubMed ID: 25574957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia.
    Napravnik S; Edwards D; Stewart P; Stalzer B; Matteson E; Eron JJ
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):34-40. PubMed ID: 16123679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.
    Pai NP; Lawrence J; Reingold AL; Tulsky JP
    Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD006148. PubMed ID: 16856117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses.
    Rojas Sánchez P; de Mulder M; Fernandez-Cooke E; Prieto L; Rojo P; Jiménez de Ory S; José Mellado M; Navarro M; Tomas Ramos J; Holguín Á;
    Clin Microbiol Infect; 2015 Jun; 21(6):605.e1-9. PubMed ID: 25680310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
    Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda.
    Mutwa PR; Boer KR; Rusine J; Muganga N; Tuyishimire D; Schuurman R; Reiss P; Lange JM; Geelen SP
    Pediatr Infect Dis J; 2014 Jan; 33(1):63-9. PubMed ID: 24352189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.
    Oliveira MI; Romão de Souza Junior V; Fernanda de Lacerda Vidal C; Sérgio Ramos de Araújo P
    BMC Infect Dis; 2018 Oct; 18(1):514. PubMed ID: 30314470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
    Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
    AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
    J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High rates of baseline antiretroviral resistance among HIV-infected pregnant women in an HIV referral centre in Rio de Janeiro, Brazil.
    de Lourdes Teixeira M; Nafea S; Yeganeh N; Santos E; Gouvea MI; Joao E; Ceci L; Bressan C; Cruz ML; Sidi LC; Nielsen-Saines K
    Int J STD AIDS; 2015 Nov; 26(13):922-8. PubMed ID: 25504831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
    Sun Z; Ouyang J; Zhao B; An M; Wang L; Ding H; Han X
    BMC Infect Dis; 2020 Feb; 20(1):178. PubMed ID: 32102660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.
    Palmisano L; Giuliano M; Galluzzo CM; Amici R; Andreotti M; Weimer LE; Pirillo MF; Fragola V; Bucciardini R; Vella S
    HIV Med; 2009 Sep; 10(8):477-81. PubMed ID: 19459989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan.
    Chang SY; Chen MY; Lee CN; Sun HY; Ko W; Chang SF; Chang KL; Hsieh SM; Sheng WH; Liu WC; Wu CH; Kao CL; Hung CC; Chang SC
    J Antimicrob Chemother; 2008 Mar; 61(3):689-93. PubMed ID: 18227088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention.
    Wohl AR; Garland WH; Valencia R; Squires K; Witt MD; Kovacs A; Larsen R; Hader S; Anthony MN; Weidle PJ
    Clin Infect Dis; 2006 Jun; 42(11):1619-27. PubMed ID: 16652320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy.
    Ormaasen V; Sandvik L; Asjø B; Holberg-Petersen M; Gaarder PI; Bruun JN
    HIV Med; 2004 Nov; 5(6):400-6. PubMed ID: 15544691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in São Paulo State, Brazil.
    Soldi GFR; Ribeiro IC; Ahagon CM; Coelho LPO; Cabral GB; Lopes GISL; Ferreira JLP; Brígido LFM;
    PLoS One; 2019; 14(10):e0223210. PubMed ID: 31574109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.
    Ortu M; Vitiello P; Adorni F; Rossotti R; Di Vincenzo P; Vigano O; Galli M; Rusconi S
    Curr HIV Res; 2011 Dec; 9(8):625-9. PubMed ID: 22211659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.